Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insider Analysis From Anand & Anand, New Dehli: What’s The Secret Behind Your Medicine? Exclusivity Or Protection Of Clinical Trial Data In India (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

By M. S. Bharath, Partner, Anand & Anand, New Dehli, India

You may also be interested in...



Indian Pharmaceutical Alliance Questions Data Exclusivity Survey; Says Transparency Lacking

NEW DELHI - The Indian Pharmaceutical Alliance - an association representing 12 leading Indian pharmaceutical companies - has raised strong opposition to a survey on data exclusivity being conducted by the New Delhi-based law firm Anand and Anand

Indian Pharmaceutical Alliance Questions Data Exclusivity Survey; Says Transparency Lacking

NEW DELHI - The Indian Pharmaceutical Alliance - an association representing 12 leading Indian pharmaceutical companies - has raised strong opposition to a survey on data exclusivity being conducted by the New Delhi-based law firm Anand and Anand

Johnson & Johnson Establishes Beijing Diabetes Institute

Johnson & Johnson has established its diabetes institute in Beijing, one of the company's first batch of four non-commercial institutes worldwide. The facility provides a free training platform for China's diabetes educators and managers. Over the next three years, the institute will work with the Ministry of Health to bring together local and overseas specialists and academics in the field to explore new standardized models with Chinese characteristics for managing the disease. Analysts believe the diabetes management model will allow China to maximize its health care resources to derive the most social benefits, especially previously idle community resources. (Click here for more - Chinese Language)

UsernamePublicRestriction

Register

LL1132940

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel